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This study evaluated whether the effect of tiotropium on the change in trough forced expiratory volume in 1 s (FEV1), vs. placebo, is
affected by smoking status. In a 3-month, double-blind study in 31 centres in Portugal, 311 (289 completed) patients were randomised to
tiotropium 18mg once daily or placebo. Baseline mean (standard deviation (SD)) FEV1 was 1.11 (0.39) l in the tiotropium group and 1.13
(0.39) l in the placebo group. Patients had an average smoking history of 55 (25.7) pack-years; 80 (26%) were smokers and 224 (74%)
were ex-smokers. The primary end-point was change in morning pre-dose (i.e. trough) FEV1 after 12 weeks. Trough FEV1 at 12 weeks
was signiﬁcantly improved with tiotropium vs. placebo: the difference in means was 102ml, P ¼ 0.0011, 95% conﬁdence interval (CI)
(41, 164). The difference in means in smokers was 138ml, P ¼ 0.0105, CI (32, 244); in ex-smokers it was 66ml, P ¼ 0.0375, CI (3, 129).
The difference between smokers and ex-smokers was not statistically signiﬁcant (P ¼ 0.6982) and may be due to greater variability and
differences in disease severity. The signiﬁcant improvement in lung function in patients treated with tiotropium vs. placebo in both
smokers and ex-smokers suggests that tiotropium is an effective and well-tolerated therapy in chronic obstructive pulmonary disease
(COPD), regardless of smoking status.
r 2007 Elsevier Ltd. All rights reserved.
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Cigarette smoking is a major risk factor for the
development of chronic obstructive pulmonary disease
(COPD) in susceptible individuals worldwide and may
account for up to 90% of the risk in developed countries
[1–3]. Evidence suggests that the number of years spent as a
smoker and amount of cigarettes smoked impacts on the
prevalence of respiratory symptoms, exacerbations, rate of
decline in lung function (i.e. forced expiratory volume in 1 s
[FEV1]) and COPD-related mortality [4–7]. Cigarette
smoking is thought to exert its effects via increasede front matter r 2007 Elsevier Ltd. All rights reserved.
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ess: joaquimmoita@chc.min-saude.pt (J. Moita).inﬂammation, airway wall ﬁbrosis, destruction of alveolar
attachments, and inhibition of repair mechanisms [2,8].
Currently, smoking cessation is the only intervention
shown to slow the long-term progression of airﬂow
obstruction as measured by the decline in FEV1 [1].
However, smoking cessation is far from easy and smoking
cessation programmes generally have poor success rates
[9–11]. Evidence also suggests that chronic inﬂammation
persists after smoking has stopped [12], which will continue
to contribute to lung function decline. Hence, it is
important to identify treatments that beneﬁt patients with
COPD, despite the fact that they might continue to smoke.
Tiotropium is a once-daily maintenance treatment
for COPD that provides 24 h efﬁcacy due to prolonged
M3-receptor antagonism. It has consistently been shown to
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and reduce dyspnoea in patients with COPD [13–15].
Post hoc analysis of two combined 1-yr placebo trials has
also provided preliminary evidence to suggest that long-
term maintenance treatment with tiotropium once daily
may slow the decline in trough (i.e. morning pre-dose)
FEV1 compared with placebo [16]; a possibility that is
currently speciﬁcally being investigated in a 4-year
prospective trial [17].
The rationale for performing this trial was based on a
meta-analysis from seven clinical trials with the shorter-
acting anticholinergic, ipratropium, in patients with
moderate to severe COPD, which suggested that the
improvement in baseline lung function in ipratropium-
treated patients was greater in ex-smokers than in smokers
[18]. The aim of this study, entitled ‘Spirivas Assessment
of FEV1’ (SAFE), was to evaluate whether the effect of
tiotropium on the change in trough FEV1 is affected by
smoking status.
2. Methods
2.1. Study design
This was a randomised, double-blind, parallel-group,
placebo-controlled, 3-month study conducted in 31 centres
in Portugal. The study (]205.282) was designed to
determine whether the effect of tiotropium on trough
FEV1 in patients with COPD was affected by smoking
status. The study was approved by regulatory and ethics
committees at all centres.
2.2. Subjects
Males or females aged X40 years with a diagnosis of
COPD (FEV1 p70% of predicted and FEV1/forced vital
capacity (FVC)p70% [19]) and a smoking history ofX10
pack-years were eligible for inclusion.
Patients were asked about their smoking status on the
ﬁrst visit. Smoking status consisted of two categories:
smokers and ex-smokers (0 cigarettes/day).
Patients were not included if they had a history of
asthma, allergic rhinitis, atopy, myocardial infarction,
unstable arrhythmia, or if they had any clinically sig-
niﬁcant disease that might put the patient at risk because of
study participation. Patients with X3 exacerbations of
COPD in the preceding year or an exacerbation or lower
respiratory tract infection within the 6 weeks prior to
randomisation were also excluded.
Concomitant use of prn salbutamol MDI (100 mg/puff;
withheld for at least 6 h prior to each clinic visit), long-
acting b2-agonists and continued use of theophylline
preparations (excluding 24 h preparations) (both withheld
for at least 24 h prior to each clinic visit) were allowed
during the study period. Concomitant use of mucolytics,
orally inhaled corticosteroids, minimal doses of oral
corticosteroids (equivalent to prednisone p10mg/day orp20mg/alternate days) were allowed if the dosage was
stabilised for at least 6 weeks before the study. Temporary
increases in the dose of theophylline preparation of p7
days or addition/increased dose of oral steroids for p2
weeks were allowed for the treatment of an exacerbation
during the study period. If appropriate, scheduled visits
were postponed for at least 1 week, but not more than 2
weeks. Use of antibiotics was not restricted. Short-acting
anticholinergics, oral b2-agonists, antileukotrienes, and
other investigational drugs were not allowed during the
study.
2.3. Assessments
After a 2-week run-in period, patients were randomised
to receive tiotropium 18 mg once daily, delivered via the
HandiHalers device (Boehringer Ingelheim, Ingelheim am
Rhein, Germany), or placebo for 12 weeks. FEV1 and FVC
were measured on test days at 10min (75min) prior to
administration of study drug (trough). Measurements were
performed in triplicate using a Datospir 120C spirometer
(Sibelmed, Barcelona, Spain) in accordance with American
Thoracic Society criteria [20].
The primary end-point was the change in trough FEV1
after 12 weeks of treatment. Trough FEV1 was measured
24 h after the previous dose of study drug on Day 1
(randomisation) as well as after 6 and 12 weeks of
treatment. Secondary end-points included trough FEV1
after 6 weeks of treatment, trough FVC after 6 and 12
weeks of treatment, assessment of COPD symptoms,
Physician’s Global Evaluation, Quality of Life Question-
naire (EQ-5D) and use of daytime and nighttime rescue
medication (salbutamol MDI 100 mg/puff). Rescue medica-
tion use, cigarette consumption and drug compliance were
recorded in patient diary cards. Adverse events were
collected throughout the study.
2.4. Statistical analysis
For the primary end-point, the comparison between
tiotropium and placebo was assessed via an analysis of
covariance (ANCOVA) model, with treatment and centre
as ﬁxed effects, and mean trough FEV1 baseline as
covariate. The primary end-point was also stratiﬁed
according to smoking status (smokers and ex-smokers),
which was added to the ANCOVA model as a ﬁxed effect.
The least square mean (LSM) for FEV1 response was
computed and compared for each treatment group,
stratiﬁed by smoking status. The secondary spirometry
measures were also analysed using a similar ANCOVA
model. The COPD symptoms and global evaluation by
investigator were analysed only descriptively. The EQ-5D
questionnaire was evaluated following EuroQol Group
Enterprise conventions [22]. Descriptive statistics were used
for safety variables.
Efﬁcacy analyses were performed using the full analysis
set (FAS), which included all patients who received at least
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who did not change smoking status during the trial. The
safety analysis set (SAS) included all patients who received
at least one dose of treatment and had one safety
evaluation after treatment.
To detect a difference of 130ml with 90% power based
on a SD of 215ml, 59 patients were required in each
treatment group. In order to obtain 59 ex-smokers in the
placebo group, based on assumed ratio of smokers to ex-
smokers of 3:2, a total of 148 patients were required in each
treatment group.Table 2
Disposition of patients
Tiotropium Placebo Total
Patients randomised (%) 147 (100.0) 164 (100.0) 311 (100.0)
Completed study according
to protocol
136 (92.5) 153 (93.3) 289 (92.9)
Reasons for premature discontinuation
Unexpected worsening of
COPD
1 (0.7) 2 (1.2) 3 (1.0)
Unexpected worsening of
other pre-existing condition
1 (0.7) 0 (0.0) 1 (0.3)
Lost to follow-up 5 (3.4) 4 (2.4) 9 (2.9)
Consent withdrawn (not
due to adverse event)
0 (0.0) 1 (0.6) 1 (0.3)
Other adverse eventsa 3 (2.0) 2 (1.2) 5 (1.6)
Other reasons 1 (0.7) 2 (1.2) 3 (1.0)
aTiotropium: cardio-respiratory arrest, chest pain, dry mouth, sudden
death; Placebo: rash, dry mouth, tremor, nausea and vomiting, constipa-
tion, weakness.3. Results
3.1. Subjects
A total of 335 patients were screened and 311 were
randomised to treatment. Seven patients changed their
smoking status during the 12 weeks after randomisation,
and were excluded from the study. A total of 304 patients
were included in the full analysis set (tiotropium: 144;
placebo: 160) (Table 1). The baseline characteristics for the
remaining 304 patients were comparable across treatment
groups (Table 1).
Patients had a mean smoking history of 55 pack-years,
and 80 (26%) were smokers and 224 (74%) were ex-
smokers. A greater proportion of ex-smokers (27%)
had very severe disease (deﬁned as FEV1/FVCo70%
and FEV1o30% predicted) compared with smokers
(19%). In the tiotropium treatment group, the study was
unable to provide smoker and ex-smoker groups with
comparable baseline characteristics for smoking history
and FEV1. Compared with ex-smokers in the tiotropium
group, smokers in the tiotropium group had a higher
pack-year smoking history (5.6 pack-years) and a
higher FEV1 (0.20 L). The percentage completing the
study according to protocol was high at 92.9% (289/311)
(Table 2).Table 1
Demographic and baseline characteristics (full analysis set)
Tiotropium (n
Non-smokers
Patients (n) 104
Males (%) 97
Age (years)a 65.778.6
Duration of COPD (years)a 14.0710.9
Smoking history (pack-years)a 54.3727.1
Duration of smoking cessation (year)a 9.179.8
Median (range) duration of smoking cessation (years) 5.6 (0.0–51.0)
FEV1 (L)
a 1.0670.37
FEV1 (% predicted)
a 38.4712.8
FVC (L)a 2.4270.76
FEV1/FVC (%)
a 44.4711.0
aMean (SD); FEV1, forced expiratory volume in 1 s; FVC, forced vital capa3.2. Efficacy assessments
In the overall group population, tiotropium signiﬁcantly
improved the mean trough FEV1 at 12 weeks compared
with placebo, with a mean difference of 102ml (P ¼ 0.001)
(Table 3).
Compared with placebo, tiotropium signiﬁcantly im-
proved mean trough FEV1 after 12 weeks in both smokers
and ex-smokers though the variability was greater with
smokers (Fig. 1). At study end, the mean difference
between the tiotropium and placebo groups was 138ml
(P ¼ 0.011) in the smokers group, and 66ml (P ¼ 0.038) in
the ex-smokers group. The difference between smokers and
ex-smokers was not statistically signiﬁcant (P ¼ 0.698).
A similar trend was also observed for trough FEV1 at 6
weeks. The mean difference between the tiotropium and
placebo groups was 94ml (95% CI: 154, 34; P ¼ 0.022).
The difference between treatment groups was 121ml
(95% CI: 226, 15; P ¼ 0.025) for smokers and 67ml¼ 144) Placebo (n ¼ 160)
Smokers Non-smokers Smokers
40 120 40
93 95 93
61.679.8 65.779.0 64.077.2
9.476.8 13.7710.5 12.378.5
59.9723.4 54.3726.7 55.3717.3
0.070.0 10.2710.4 0.070.0
0.070.0 6.1 (0.0–55.0) 0.070.0
1.2670.42 1.1370.40 1.1570.40
44.4713.9 42.3715.3 40.4714.5
2.6870.73 2.5270.69 2.5470.71
47.9713.7 45.2711.5 46.7713.4
city.
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Table 3
Trough FEV1 and FVC response (tiotropium–placebo) for change from baseline values at 12 weeks by smoking status
FEV1 FVC
Difference, LSM (ml) 95% CI P-value Difference, LSM (ml) 95% CI P-value
All patients 102 41, 164 0.0011 164 58, 270 0.0024
Smokers 138 32, 244 0.0105 158 23, 341 0.0870
Ex-smokers 66 3, 129 0.0375 170 62, 278 0.0021
LSM, least square means; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity. *Differences between smoking groups were not signiﬁcant
(P ¼ 0.6982 for FEV1 and P ¼ 0.5220 for FVC).
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Fig. 1. Mean change in trough FEV1 during the 12-week study by treatment group and smoking status: (a) smokers and (b) ex-smokers.
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Fig. 2. Mean change (tiotropium–placebo) in daytime rescue medication
use in smokers and ex-smokers.
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evidence of tachyphylaxis (Fig. 1).
The mean change from baseline in trough FEV1 was
generally higher in smokers than in ex-smokers.
Tiotropium signiﬁcantly improved mean trough
FVC after 12 weeks compared with placebo (P ¼ 0.019)
(Table 3). Improvements compared with placebo occurred
in both smokers and ex-smokers, though they were
signiﬁcant only in ex-smokers. However, the difference
between responses to tiotropium in smokers and ex-
smokers was not statistically signiﬁcant (P ¼ 0.535).
Compared with placebo, patients in the tiotropium
group used fewer doses of daytime and nighttime rescue
medication during the study. This difference tended to
increase over the 12-week treatment period. The difference
in daytime usage between placebo and tiotropium was
signiﬁcant at weeks 2, 6, 8, 11 and 12 (Po0.05). The
magnitude of the reduction in daytime rescue medication
use with tiotropium compared with placebo tended to be
greater in smokers than ex-smokers in the latter 6 weeks of
treatment (Fig. 2). Similar trends were seen with nighttime
rescue medication.
COPD symptoms, global evaluation by the investigator
and the EQ-5D showed no differences between treatment
groups.3.3. Safety assessment
The proportion of patients experiencing at least one
adverse event during the study was 11.6% in the
tiotropium group and 15.9% in the placebo group. Six
patients (4.1%) in the tiotropium group and three patients
(1.8%) in the placebo group experienced a serious adverse
event, including two deaths (both in the tiotropium group),
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Table 4
Adverse event proﬁle
Tiotropium Placebo
Patients (n)a 147 164
Serious adverse events 6 (4.1) 3 (1.8)
Patients with adverse events 17 (11.6) 26 (15.9)
Cardiac disorders 2 (1.4) 1 (0.6)
Eye disorders 0 (0.0) 1 (0.6)
Gastrointestinal disorders 3 (2.0) 2 (1.2)
General disorders 6 (4.1) 5 (3.0)
Infections and infestations 1 (0.7) 1 (0.6)
Musculoskeletal and connective tissue
disorders
1 (0.7) 2 (1.2)
Nervous system disorders 1 (0.7) 5 (3.0)
Lower respiratory system disorders
(excluding exacerbations)
3 (2.0) 6 (3.7)
Exacerbations 6 (4.1) 6 (3.7)
Upper respiratory system disorders 4 (2.7) 4 (2.4)
Skin and subcutaneous disorders 0 (0.0) 1 (0.6)
Data are presented as n (%) unless otherwise indicated.
aAnalysis includes all 311 patients (i.e, including the seven patients who
changed their smoking status during the trial).
J. Moita et al. / Pulmonary Pharmacology & Therapeutics 21 (2008) 146–151150but none of these nine events was considered to be related
to study medication.
Respiratory system disorders were distributed in three
different groups: lower (including COPD exacerbations),
upper and other. The results showed that the most
commonly reported adverse events in both the tiotropium
and placebo groups were: lower respiratory disorders
(18.3% and 20.1%, respectively); and upper respiratory
disorders (5.4% and 4.9%, respectively) (Table 4).
4. Discussion
The aim of this study was to determine whether the effect
of inhaled tiotropium on lung function in patients with
COPD was affected by smoking status. The primary
outcome of this study showed that there was a signiﬁcant
improvement in trough FEV1 after 12 weeks’ treatment
with tiotropium compared with placebo, irrespective of
smoking status. These data were supported, at least in part,
by the secondary outcomes.
The use of short-acting bronchodilators for symptomatic
relief provides an indication of the degree of dyspnoea
experienced by the patient. Tiotropium reduced daytime
and nighttime rescue medication compared with placebo
during the study, and the difference between active
treatment and placebo tended to increase over the 12-week
treatment period. Subgroup analysis suggests that the
mean response to tiotropium for reduction of daytime use
of rescue medication was signiﬁcantly greater in smokers
compared with ex-smokers. However, though a trend was
evident at other time points, this result may be related to
greater variability within these subgroups and differences
in disease severity.
There have been few studies speciﬁcally analysing the
relationship between bronchodilators and smoking status.A meta-analysis of seven trials in moderate to severe
COPD has suggested that the bronchodilator response to
the anticholinergic ipratropium may be greater in ex-
smokers compared with smokers [18]. Examination of the
subgroup of ex-smokers in these trials showed them to have
a baseline FEV1 of about 20% less than smokers. Hence,
the authors of the meta-analysis suggested that the greater
response with ipratropium in ex-smokers might be related
to more severe impairment of lung function. This result
could have relevance in the interpretation of the Lung
Health Study, which suggested no sustained additional
effect of ipratropium on the reduced rate of decline in lung
function as a result of a smoking cessation programme [21].
The Lung Health Study recruited only current smokers,
which, in addition to the reported use of an average of two
doses of ipratropium per day rather than the prescribed 3–4
doses per day, could have limited the effect of ipratropium
compared with that which may occur in long-term ex-
smokers.
Ideally, interventions in COPD need to be effective in
both smokers and ex-smokers, particularly as many
patients ﬁnd it difﬁcult to stop smoking. However,
smoking cessation must be viewed as the most important
therapeutic intervention for those who continue to smoke
and should be encouraged with the latest advances in
treating nicotine addiction whenever feasible. Bronchodi-
lators are considered ﬁrst-line maintenance therapy in the
management of symptomatic COPD [1]. Hence, the results
of the current study showing beneﬁcial effects of tiotro-
pium treatment on lung function in both smokers and ex-
smokers are encouraging. A trend for greater responses
with tiotropium in smokers, which is in contrast to the
ﬁndings with ipratropium, may be suggested from some
data in this trial. Data from smokers showed greater
variability than data from ex-smokers and a greater
proportion of ex-smokers had more severe disease than
smokers, both of which may account for the lack of
statistical signiﬁcance between groups. More severe disease
in ex-smokers was also shown in patients recruited in
1-year study trials with tiotropium [16]. In this case, the
authors speculated that patients with more rapidly
progressing disease are more likely to have the incentive
to stop smoking successfully compared with those with
more gradual disease progression.
There are several limitations to the current study. First,
according to the protocol, the proportions of smokers and
ex-smokers were expected to be 60% and 40%, respec-
tively. However, the proportions were modiﬁed to 32%
smokers and 68% ex-smokers in order to achieve at least
85% statistical power in the analyses of smokers. Due to
enrolment difﬁculties the ratio of smokers to ex-smokers
became more disproportionate. As seven patients changed
their smoking status during the study and were excluded
from the analyses, a total of 80 smokers were included in
the trial (26.3% instead of the expected 32%; 40 smokers
per treatment arm), with this ratio the statistical power in
the analyses of smokers was 75%. Consequently, the
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than planned in the protocol, which may have increased the
variability in the data in the smokers subgroup. Second, as
smoking abstinence was not veriﬁed by saliva cotinine or
expired carbon monoxide some patients may have been
misclassiﬁed. Third, the duration of 12 weeks may not be
representative of the long-term effects of maintenance
treatment with tiotropium in patients with COPD stratiﬁed
by smoking status. Hence, further data from large, long-
term trials with tiotropium, such as the ongoing, 4-year
understanding potential long-term impacts on function
with tiotropium (UPLIFT) trial [17] are required to
conﬁrm these results.
In summary, tiotropium signiﬁcantly improved lung
function in both smokers and ex-smokers compared with
placebo. This, combined with a favourable safety proﬁle
from this trial, suggests that tiotropium is an effective and
well-tolerated therapy in COPD, regardless of smoking
status.
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